MetaVia Inc.

MTVA

NASDAQ

Healthcare

Biotechnology

Cambridge, MA, US9 employeesmetaviatx.com

$1.26

+0.01(0.80%)

Mkt Cap $3M

$1.17

$20.24

52-Week Range

At a Glance

AI-generated

MetaVia Inc.

8-K

MetaVia Inc. announced financial results for the year ended December 31, 2025, reporting net loss of $13.0 million or $7.35 per share, R&D expenses of $6.8 million, G&A expenses of $6.9 million, and cash of $10.3 million. The company highlighted positive Phase 1 data for DA-1726 showing 9.1% weight loss and upcoming Phase 1 Part 3 study initiation in April 2026.

$3M

Market Cap

—

Revenue

-$16M

Net Income

Employees9

Fundamentals

How The Business Makes Money

MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.

Industry Biotechnology

Activity

What Changed Recently

Management Change

Jan 26, 2026

(f) of Form 8-K, set forth below is an updated “Summary Compensation Table for 2025 and 2024”, which includes the amount of discretionary cash bonuses payable t

Financial Results

Mar 25, 2026

and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the

Material Agreement

Jan 15, 2026

Entry into a Material Definitive Agreement. On January 15, 2026, MetaVia Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agree

Financial Results

Jan 4, 2026

of this Current Report on Form 8-K (this “Report”) is furnished pursuant to Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securiti

Regulation FD

Jan 4, 2026

of this Report, including Exhibit 99.1 attached hereto, is furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Sec

Peer Companies

Company	Price	Change	Market Cap	P/E
LSTALisata Therapeutics, Inc.	$5.01	+0.10%	$45M	-2.6
XCURExicure, Inc.	$4.22	+0.96%	$27M	-3.0
PASGPassage Bio, Inc.	$8.18	+4.20%	$26M	-0.5
ENLVEnlivex Therapeutics Ltd.	$0.98	+1.78%	$24M	-2.1
KLTOKlotho Neurosciences, Inc...	$0.38	-7.10%	$20M	—
NCNANuCana plc	$1.66	+7.47%	$10M	-0.1
SONNSONN	$1.26	-59.35%	$8M	—
CLGNCollPlant Biotechnologies...	$0.49	-8.20%	$6M	-0.6

Analyst View

Company Profile

CIK0001638287

ISINUS64132R5037

Phone857 702 9600

Address545 Concord Avenue, Cambridge, MA, 02138, US

SEC EDGAR